Quintiles Transitional Holdings Inc. (Q) Director Dennis B. Ph D. Gillings Sells 968,023 Shares
Quintiles Transitional Holdings Inc. (NYSE:Q) Director Dennis B. Ph D. Gillings sold 968,023 shares of the stock in a transaction dated Monday, August 28th. The shares were sold at an average price of $97.33, for a total value of $94,217,678.59. Following the completion of the transaction, the director now directly owns 9,071,839 shares in the company, valued at approximately $882,962,089.87. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Quintiles Transitional Holdings Inc. (NYSE Q) traded down 0.16% during mid-day trading on Thursday, hitting $95.64. The stock had a trading volume of 769,245 shares. Quintiles Transitional Holdings Inc. has a 1-year low of $70.10 and a 1-year high of $99.95. The stock has a market cap of $20.71 billion, a PE ratio of 277.22 and a beta of 0.64. The firm’s 50-day moving average price is $91.06 and its 200-day moving average price is $84.68.
Quintiles Transitional Holdings (NYSE:Q) last issued its quarterly earnings data on Thursday, August 3rd. The medical research company reported $1.09 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.05 by $0.04. Quintiles Transitional Holdings had a return on equity of 14.23% and a net margin of 0.82%. The company had revenue of $1.97 billion for the quarter, compared to the consensus estimate of $1.96 billion. During the same quarter last year, the business posted $0.93 earnings per share. The firm’s revenue was up 68.7% compared to the same quarter last year. On average, equities analysts expect that Quintiles Transitional Holdings Inc. will post $4.58 earnings per share for the current year.
Quintiles Transitional Holdings announced that its Board of Directors has initiated a share buyback program on Wednesday, May 24th that allows the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization allows the medical research company to buy up to 5.4% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board believes its stock is undervalued.
Several large investors have recently modified their holdings of Q. Fiduciary Trust Co. acquired a new stake in shares of Quintiles Transitional Holdings during the second quarter worth about $105,000. Global X Management Co. LLC increased its stake in shares of Quintiles Transitional Holdings by 30.8% in the first quarter. Global X Management Co. LLC now owns 1,469 shares of the medical research company’s stock worth $118,000 after buying an additional 346 shares during the period. GWM Advisors LLC acquired a new stake in shares of Quintiles Transitional Holdings during the second quarter worth about $122,000. Korea Investment CORP increased its stake in shares of Quintiles Transitional Holdings by 142.5% in the second quarter. Korea Investment CORP now owns 1,370 shares of the medical research company’s stock worth $123,000 after buying an additional 805 shares during the period. Finally, IFP Advisors Inc increased its stake in shares of Quintiles Transitional Holdings by 187.1% in the first quarter. IFP Advisors Inc now owns 1,774 shares of the medical research company’s stock worth $143,000 after buying an additional 1,156 shares during the period. Institutional investors own 91.36% of the company’s stock.
Several equities analysts have weighed in on the company. Barclays PLC reissued an “overweight” rating and issued a $98.00 target price (up previously from $90.00) on shares of Quintiles Transitional Holdings in a research note on Monday, July 17th. William Blair raised Quintiles Transitional Holdings from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $70.10 to $93.42 in a research report on Friday, August 4th. Jefferies Group LLC reaffirmed a “hold” rating and set a $94.00 price target on shares of Quintiles Transitional Holdings in a research report on Friday, August 4th. Citigroup Inc. raised their price target on Quintiles Transitional Holdings from $96.00 to $97.00 and gave the stock a “neutral” rating in a research report on Monday, August 7th. Finally, Stifel Nicolaus reaffirmed a “hold” rating and set a $92.00 price target (up previously from $87.00) on shares of Quintiles Transitional Holdings in a research report on Friday, August 4th. Eleven research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $90.25.
Quintiles Transitional Holdings Company Profile
Quintiles IMS Holdings, Inc, formerly Quintiles Transnational Holdings Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
Receive News & Ratings for Quintiles Transitional Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quintiles Transitional Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.